Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Devices and methods for analysing extracellular vesicle glycans are described. According to an embodiment, a microfluidic device comprises an inlet portion configured to receive a fluid sample; a mixing portion fluidically coupled to the inlet portion and configured to facilitate mixing between the fluid sample and magnetic nanoparticles functionalized to bind with extracellular vesicles and aggregate to vesicle glycans in the fluid sample; a magnetic separation portion fluidically coupled to the mixing portion and configured to separate clusters of magnetic nanoparticles from the fluid sample; and a magnetic sensor configured to measure magnetic properties of the fluid sample after it has passed through the magnetic separation portion. The magnetic nanoparticles may configured to aggregate in the presence of respective lectins when bound with extracellular vesicles carrying target glycans. In a specific embodiment, the magnetic particles comprise a magnetic polycore coated with polydopamine.

The present disclosure provides, inter alia, methods for identifying cells undergoing non-apoptotic cell death, e.g., ferroptosis, in a subject, using anti-TfR1 antibodies such as 3F3-FMA. Methods for treating or ameliorating the effects of a cancer in a subject, methods for enhancing the anti-tumor effect of radiation in a subject with cancer undergoing radiotherapy, and compositions and kits comprising anti-TfR1 antibodies disclosed herein are also provided.

The present disclosure provides a therapy for diabetes that targets abnormal stem cells in combination with stem cell migration. In one embodiment, the present disclosure provides a therapy for diabetes and/or diabetes-related diseases and disorders and/or symptoms that targets abnormal stem cells in combination with stem cell migration. In one embodiment, the present disclosure provides diagnosis of diabetes and/or diabetes-related diseases and disorders and/or symptoms, or the risk thereof, using abnormal stem cell migration and/or residence as an indicator.

As a technique enabling to simply and accurately diagnose human T cell leukemia virus type 1 (HTLV-1) related disease, there is provided a diagnostic method for an HTLV-1 related disease based on an amount of tumor necrosis factor receptor 2 (TNFR2) in a blood sample taken from a subject, wherein (1) it is determined based on an increase of the amount of TNFR2 that the subject suffers from, or is likely to develop, the HTLV-1 related disease; and/or (2) it is determined based on a decrease of the amount of TNFR2 that the subject is in remission, or is likely to be in remission, of the HTLV-1 related disease.

The present invention is based, in part, on the discovery of anti-PSGL-1 compositions (e.g., monoclonal antibodies and antigen-binding fragments thereof) that regulate myeloid cell inflammatory phenotypes, such as suppressive myeloid cells, monocytes, macrophages, neutrophils, and/or dendritic cells, including polarization, activation, and/or function, and methods of using such anti-PSGL-1 compositions for therapeutic, diagnostic, prognostic, and screening purposes.

Provided herein are polypeptides which include tenth fibronectin type III domains (.sup.10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a .sup.10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 .sup.10Fn3 drug conjugates are also provided.

The invention relates to the field of diagnostic immunology. Provided are means and methods for multiparameter cytometry-based leukocyte subsetting, which is advantageously used for the monitoring of the immune status of a subject, and/or for monitoring the effects of an immune modulatory treatment. Provided among others is a reagent composition comprising antibodies conjugated to a detectable label, the conjugated antibodies being directed against the following combination of markers: CD141, HLA-DR, CD16, CD33, CD300e, CD303 and CD14, wherein the antibodies directed against CD300e and CD303 may be conjugated to the same label.

Provided are novel rhodol-based compounds, the preparation method thereof, and use thereof in Tl.sup.+ flux assays. The fluorescent thallium ion sensor compounds have a rhodol fluorophore attached to an amino dicarboxylic acid metal binding moiety. The compounds are prepared in the “pro-dye” form, with the rhodol oxygen and the carboxylic acids of the metal binding unit masked by protecting groups. The disclosed compounds may be used as more red-shifted and less pH-sensitive variants of Thallos.

Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3). Also disclosed are conjugates and compositions that include the peptides and/or peptidomimetics, methods for directing a moiety to tumor lymphatic vasculature, methods for imaging tumor lymphatic vasculature, methods for reducing or inhibiting tumor metastasis, methods for reducing the number of tumor lymphatic vessels, methods for treating cancer, methods for treating a disease or disorder associated with a gC1q/p32 receptor biological activity, methods for detecting the presence of a gC1q/p32 receptor, methods for detecting interactions between gC1q/p32 receptors and the presently disclosed conjugates and compositions, methods for delivering the presently disclosed conjugates and compositions to gC1q/p32 receptors, methods for assessing gC1q/p32 receptor levels in cells, methods for identifying subjects having diseases associated with gC1q/p32 receptor biological activities, and methods for screening for compounds that interact with gC1q/p32 receptors.